Combined vaccines for prophylaxis of infectious conditions

References

• Vaccines [Internet]. World Health Organization; 2018; [cited 2018 Oct 15]. Available from: http://www.who.int/topics/vaccines/en/
   Google Scholar
• Skibinski D, Baudner B, Singh M, et al. Combination vaccines. J Glob Infect Dis. 2011;3:63.
   PubMedGoogle Scholar
• Gautret P, Wilder-Smith A. Vaccination against tetanus, diphtheria, pertussis, and poliomyelitis in adult travelers. Travel Med Infect Dis. 2010;8:155–160.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Choi JH. Tetanus–diphtheria–acellular pertussis vaccination for adults: an update. Clin Exp Vac. 2017;6:22–30.
   PubMed Web of Science ®Google Scholar
• Vaccine Position Papers [Internet]. World Health Organization; 2018; [cited 2018 Oct 15]. Available from: http://www.who.int/immunization/documents/positionpapers/en/.Sanofi. Pasteur Inc. Diphtheria and tetanus toxoids and acellular pertussis adsorbed inactivated poliovirus and Haemophilus b conjugate (tetanus toxoid conjugate) vaccine (Pentacel): US product information. Available from: http://www.fda.gov/cber/label/pentacelLB.pdf
   Google Scholar
• Gold R, Barreto L, Ferro S, et al. Safety and immunogenicity of a fully liquid vaccine containing five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus influenza type B conjugate vaccines administered at two, four, six and 18 months of age. Can J Infect Dis Med Microbiol. 2007;18:241–248.
   PubMed Web of Science ®Google Scholar
• Dhillon S, Keam SJ. DTaP-IPV/Hib vaccine (Pentacel)®. Paediatr Drugs. 2008;10:405–416.
   PubMedGoogle Scholar
• McCormack PL. DTaP-IPV-Hep B-Hib Vaccine (Hexaxim®): a review of its use in primary and booster vaccination®. Paediatr Drugs. 2013;15:59–70.
   PubMed Web of Science ®Google Scholar
• Sood A, Mitra M, Joshi HA, et al. Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27/3 rubella strain: results of a randomized, comparative, active-controlled phase III clinical trial. Hum Vac Immunother. 2017;13:1523–1530.
   PubMed Web of Science ®Google Scholar
• Ma S, Li X, Xiong Y, et al. Combination measles–mumps–rubella–varicella vaccine in healthy children. Medicine. 2015;94:1–10.
   Web of Science ®Google Scholar
• Marin M, Broder KR, Temte JL, et al. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59:1–12.
   PubMedGoogle Scholar
• Lambert PH, Liu M, Siegrist CA. Can successful vaccines teach us how to induce efficient protective immune responses? Nat Med. 2005;11:54.
   PubMed Web of Science ®Google Scholar
• Peeters CC, Lagerman PR, de Weers O, et al. Preparation of polysaccharide-conjugate vaccines. In: Vaccine protocols. Humana Press; 2003. p. 153–173.
   Google Scholar
• Caporuscio S, Ieraci R, Valesini G, et al. Anti-polysaccharide and anti-diphtheria protective antibodies after 13-valent pneumococcal conjugate vaccination in rheumatoid arthritis patients under immunosuppressive therapy. Clin Immunol. 2018;195:18–27.
   PubMed Web of Science ®Google Scholar
• Bardotti A, Averani G, Berti F, et al. Size determination of bacterial capsular oligosaccharides used to prepare conjugate vaccines against Neisseria meningitides groups Y and W135. Vaccine. 2005;23:1887–1899.
   PubMed Web of Science ®Google Scholar
• Ferlito C, Biselli R, Cattaruzza MS, et al. Immunogenicity of meningococcal polysaccharide ACWY vaccine in primary immunized or revaccinated adults. Clin Exp Immunol. 2018;194:361–370.
   PubMed Web of Science ®Google Scholar
• Jodar L, Griffiths E, Feavers I. Scientific challenges for the quality control and production of group C meningococcal conjugate vaccines. Vaccine. 2004;22:1047–1053.
   PubMed Web of Science ®Google Scholar
• Immunology and Vaccine-Preventable Diseases – Pink Book; [Internet]. Cdc.gov.; 2018; [cited 2018 Oct 15]. Available from: https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/prinvac.pdf
   Google Scholar
• Lesinski G, Julie Westerink M. Vaccines against polysaccharide antigens. CDTID. 2001;1:325–334, 225–334.
   Google Scholar
• Guzman CA, Borsutzky S, Griot-Wenk M, et al. Vaccines against typhoid fever. Vaccine. 2006;24:3804–3811.
   PubMed Web of Science ®Google Scholar
• Kothari S, Kothari N, Lee E, et al. Development of an efficient and scalable method for processing and purification of Vi capsular polysaccharide. Proc Vaccinol. 2010;2:78–81.
   Google Scholar
• Szu SC, Taylor DN, Trofa AC, et al. Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines. Infect Immun. 1994;62:4440–4444.
   PubMed Web of Science ®Google Scholar
• Steel HC, Cockeran R, Anderson R, et al. Overview of community-acquired pneumonia and the role of inflammatory mechanisms in the immunopathogenesis of severe pneumococcal disease. Mediat Inflamm. 2013;2013:1.
   Web of Science ®Google Scholar
• Pitsiou GG, Kioumis IP. Pneumococcal vaccination in adults: does it really work? Respir Med. 2011;105:1776–1783.
   PubMed Web of Science ®Google Scholar
• Daniels CC, Rogers PD, Shelton CM. A review of pneumococcal vaccines: current polysaccharide vaccine recommendations and future protein antigens. J Pediatr Pharmacol Ther. 2016;21:27–35.
   PubMedGoogle Scholar
• Pietersz GA, Esparon SE, Proudfoot O, inventors. MacFarlane Burnet Centre for Medical Res Ltd-Fairfield Hospital, assignee. Flu vaccine admixture of mannan and flu antigen. United States patent US 8,182,821. 2012 May 22.
   Google Scholar
• Stambas J, Pietersz G, McKenzie I, et al. Oxidised mannan as a novel adjuvant inducing mucosal IgA production. Vaccine. 2002;20:1068–1078.
   PubMed Web of Science ®Google Scholar
• Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med. 2013;19:1597.
   PubMed Web of Science ®Google Scholar
• Hogen Esch H. Mechanism of immunopotentiation and safety of aluminum adjuvants. Front Immunol. 2013;3:406.
   PubMed Web of Science ®Google Scholar
• Bansal V, Kumar M, Bhardwaj A, et al. In vivo efficacy and toxicity evaluation of polycaprolactone nanoparticles and aluminum based admixture formulation as vaccine delivery system. Vaccine. 2015;33:5623–5632.
   PubMed Web of Science ®Google Scholar
• Mbow ML, De Gregorio E, Valiante NM, et al. New adjuvants for human vaccines. Curr Opin Immunol. 2010;22:411–416.
   PubMed Web of Science ®Google Scholar
• Milanetti F, Germano V, Nisini R, et al. Safety and immunogenicity of co‐administered MF 59‐adjuvanted 2009 pandemic and plain 2009–10 seasonal influenza vaccines in rheumatoid arthritis patients on biologicals. Clin Exp Immunol. 2014;177:287–294.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Groth N, Karvonen A, et al. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second-year seasonal vaccination. Vaccine. 2009;27:6291–6295.
   PubMed Web of Science ®Google Scholar
• Kaurav M, Madan J, Sudheesh M, et al. Combined adjuvant-delivery system for new generation vaccine antigens: alliance has its own advantage. Artif Cells Nanomed Biotechnol. 2018;1–14. DOI:10.1080/21691401.2018.1513941
   Web of Science ®Google Scholar
• Harper DM. Currently approved prophylactic HPV vaccines. Expert Rev Vac. 2009;8:1663–1679.
   PubMed Web of Science ®Google Scholar
• Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin Biol Ther. 2008;8:235–247.
   PubMed Web of Science ®Google Scholar
• Li L, Lin SL, Deng L, et al. Potential use of chitosan nanoparticles for oral delivery of DNA vaccine in black seabream Acanthopagrus schlegelii bleeker to protect from Vibrio parahaemolyticus. J Fish Dis. 2013;36:987–995.
   PubMed Web of Science ®Google Scholar
• Han J, Zhao D, Li D, et al. Polymer-based nanomaterials and applications for vaccines and drugs. Polymers. 2018;10:31.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4:145.
   PubMed Web of Science ®Google Scholar
• Allison AC, Gregoriadis G. Liposomes as immunological adjuvants. Nature. 1974;252:252.
   PubMed Web of Science ®Google Scholar
• Carstens MG, Camps MG, Henriksen-Lacey M, et al. Effect of vesicle size on tissue localization and immunogenicity of liposomal DNA vaccines. Vaccine. 2011;29:4761–4770.
   PubMed Web of Science ®Google Scholar
• Ribeiro AM, Souza ACO, Amaral AC, et al. Nanobiotechnological approaches to delivery of DNA vaccine against fungal infection. J Biomed Nanotechnol. 2013;9:221–230.
   PubMed Web of Science ®Google Scholar
• Badiee A, Khamesipour A, Samiei A, et al. The role of liposome size on the type of immune response induced in BALB/c mice against leishmaniasis: rgp63 as a model antigen. Exp Parasitol. 2012;132:403–409.
   PubMed Web of Science ®Google Scholar
• Amidi M, Van Helden M, Tabataei N, et al. Induction of humoral and cellular immune responses by antigen expressing immunostimulatory liposomes. J Control Release. 2012;164:323–330.
   PubMed Web of Science ®Google Scholar
• Christensen D, Henriksen-Lacey M, Kamath AT, et al. A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog. J Control Release. 2012;160:468–476.
   PubMed Web of Science ®Google Scholar
• Gluck R, Burri KG, Metcalfe I. Adjuvant and antigen delivery properties of virosomes. Curr Drug Deliv. 2005;2:395–400.
   PubMedGoogle Scholar
• Herzog C, Hartmann K, Künzi V, et al. Eleven years of Inflexal® V-a virosomal adjuvanted influenza vaccine. Vaccine. 2009;27:4381–4387.
   PubMed Web of Science ®Google Scholar
• Schwendener RA. Liposomes as vaccine delivery systems: a review of the recent advances. Ther Adv Vac. 2014;2:159–182.
   PubMedGoogle Scholar
• Brito LA, Kommareddy S, Maione D, et al. Self-amplifying mRNA vaccines. In: Advances in genetics, vol. 89. Massachusetts: Academic Press; 2015. p. 179–233.
   Google Scholar
• Shende P, Patel C. siRNA: an alternative treatment for diabetes and associated conditions. J Drug Target. 2019;27:174–182.
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Porter FW, et al. mRNA vaccines – a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261.
   PubMed Web of Science ®Google Scholar